Since their discovery in 2010, JQ1 and I-BET151 have shown considerable anticancer effects against leukemia [37-39], lymphoma [36], myeloma [34], lung cancer [40] and neuroblastoma [28] in vitro and in vivo, through blocking the transcription of both c-Myc and N-Myc. Here, MYCN is linked to lung carcinoma.